Objectives-Mapping of the lymphatic chain for identification of the sentinel lymph node (SLN) is an important aspect of predicting outcomes for patients with breast cancer, and it is usually performed as an intraoperative procedure using blue dye and/or radiopharmaceutical agents. Recently, the use of contrast-enhanced ultrasound (CEUS) has been proposed as an alternative imaging technique for this mapping. The objective of this study was to evaluate the use of subdermal administration of the ultrasound (US) contrast agent Sonazoid (GE Healthcare, Oslo, Norway) in terms of patient safety and to select the dose to be used for lymphatic applications in humans.
L ymph node (LN) status is considered an important predictor of long-term outcomes for patients with breast cancer, 1 which makes their mapping clinically important. This mapping is usually performed as an intraoperative procedure to identify LNs in the draining pathway of a primary tumor. 2 The sentinel lymph node (SLN) concept is based on the theory that metastatic cells spread through the lymphatic system, with the SLN being the first one in the lymphatic chain. Hence, if the SLN is free of cancer cells, the rest of the lymphatic chain will be free of metastatic disease. 3 Several techniques and imaging agents have been developed to map lymphatic drainage from tumors; the ones currently used clinically include the use of blue dye with surgical dissection and injection of radiopharmaceuticals followed by evaluation with a gamma camera (ie, lymphoscintigraphy) or intraoperatively with a gamma probe (isotope mapping). [4] [5] [6] [7] [8] [9] [10] However, studies of these approaches indicate wide variability in the accuracy for detection of SLNs ranging from 76% to 97%. [11] [12] [13] Also, there are limitations and potential adverse effects: eg, the use of blue dye requires surgical dissection that can be extensive, especially if the blue dye passes the SLNs and drains into secondary LNs, resulting in a more extensive resection. Blue dye can also cause anaphylactic reactions. Lymphoscintigraphy uses radiation, and although it is low dose, it does nonetheless involve exposure not only for the patient but also for the surgical team. Another issue with lymphoscintigraphy is that the detection of SLNs can be incomplete if they are located outside the imaging field or behind another SLN (due to the lack of anatomical information). The material used for lymphoscintography can also pass the SLNs and drain into secondary LNs, resulting in a larger resection than would otherwise be needed. 4, 5, 14, 15 Hence, there is a need for better mapping of the SLNs to avoid these pitfalls while having equal or better efficacy.
Diagnostic ultrasound (US) imaging has been used to evaluate LNs for both benign and metastatic disease. [16] [17] [18] It has also been found to be a valuable method to guide LN biopsies. 19, 20 Although grayscale US, color flow US, and pulsed Doppler US have been used alone or in combination to assess LNs for the presence of metastases, US cannot be used for lymphatic mapping (ie, to identify a tumor's SLNs) because mapping requires administration of a tracer (eg, dye or radiopharmaceutical). This paradigm changed when reports on the use of contrast-enhanced ultrasound (CEUS) to detect lymphatic channels (LCs) and LNs after subdermal injections of microbubble-based ultrasound contrast agents (UCAs) in several animal species (termed "lymphosonography") were produced. 14, 15, [21] [22] [23] Our investigations, using a Sinclair swine model with naturally occurring melanoma tumors, established that the accuracy of SLN detection was 82% for lymphosonography (293 of 351 SLNs), which was significantly higher than the 63% achieved with lymphoscintigraphy (231 of 351 SLNs; P < .0001). 15 One important benefit of lymphosonography is that the UCA remains within the SLNs and does not progress further into the lymphatic system, which is an important aspect, since an unnecessary larger resection is prejudicial for the patients. More recently, some studies have focused on the use of this technique to evaluate the presence of SLNs in humans with breast cancer, where the UCA was injected subdermally around the areola, and the LCs were followed to the axilla for the identification of SLNs. These studies demonstrated accuracy for SLN detection varying from 70% to 100%. [24] [25] [26] [27] [28] A number of different UCAs have been tested for lymphosonography; however, our animal studies indicated that the best agent available at present for this application is Sonazoid (perfluorobutane microbubbles; GE Healthcare, Oslo, Norway).
14 The use of subdermal administration of Sonazoid in terms of patient safety was assessed in this study, and the best dose was selected (from between 2 doses used in animals) for translation into lymphatic applications in human patients.
Materials and Methods

Participants
Twelve healthy volunteers were enrolled in the study, which was conducted at Thomas Jefferson University from January to April 2016. First, the volunteers went through a full demographic profile, including known drug allergies or intolerances, and a review of their medical/surgical history was recorded. Pregnant women were excluded from this study.
All volunteers provided written informed consent. The study was approved by the university's Institutional Review Board as well as the US Food and Drug Administration (IND no. 124,465) and was compliant with the Health Insurance Portability and Accountability Act.
The UCA used in this study (Sonazoid) was provided by GE Healthcare, and Siemens Healthineers (Mountain View, CA) provided the US scanner used. However, the authors had sole control of the data and information provided for publication.
Data Acquisition
The scanning part of the study was performed on 3 different days (Figure 1 ). The first day, the left breast was injected and scanned. The second day (1 week later) involved the right breast being injected and scanned. The left breast was scanned as well but only to determine whether any contrast remained from the first injection/day. The third and final day of scanning was 1 week from the second study, and it did not include UCA injections. Instead, both breasts were scanned to determine whether there was any remaining contrast.
The first day of scanning consisted of each volunteer receiving a low (1.0 mL) or high (2.0 mL) dose of Sonazoid, which was injected according to a blinded, randomized allocation schedule. The choice of these 2 doses as the possible optimal doses to use was based on prior animal studies. 14, 15, 22, 23 As part of the baseline assessments (ie, before UCA injection), the participants had their left breast, chest wall, and axilla clinically examined. Also, they underwent a baseline grayscale US examination of their left breast and axilla. First, each volunteer received a subdermal low or high dose of Sonazoid divided into 4 individual aliquots at 4 locations (12, 3, 6, and 9 o'clock) around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast. The region around the injection sites was massaged for 5 minutes by an experienced physician (J.B.L.) to accelerate the uptake of Sonazoid into the lymphatic system. A CEUS examination was performed immediately afterward (ie, lymphosonography) to identify the number, location, and course of the LCs and SLNs using Cadence Pulse Sequencing (Siemens Healthineers) on an S3000 Helx scanner (Siemens Healthineers) with a high-frequency, broad-bandwidth (4-9 MHz) linear array (9L4). Contrast-enhanced US evaluations were repeated at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 24 hours after Sonazoid administration. For each time point, the focal zone, scanning depth, and time-gain compensation were adjusted to optimize visualization of the target region (SLN or LC). No compounding or other image-processing techniques were applied. Sagittal and transverse still images and digital clips were acquired during the US examination. The safety and tolerability of Sonazoid were closely monitored throughout this dose-finding study, and any adverse experiences (AEs) were noted. The second day of scanning (1 week later), the upper outer quadrant of the right breast was injected with Sonazoid, and lymphosonography was again used to identify the number, location, and course of the LCs and SLNs, following the same protocol of the first day, described in detail above. The main difference was that the volunteers who received the low dose on their first day received the high dose on this second day and vice versa. During this second study, the left breast was also scanned one more time to assess whether there was any contrast-enhanced tissue remaining at the 1 week mark. The third and last scanning day of the study was performed around 1 week after the second day and consisted of both breasts being assessed with CEUS one last time for the presence of contrast-enhanced tissues.
Vital Signs, Blood Analysis, and Urinalysis During the study, the volunteers had their vital signs (blood pressure, heart rate, respiratory rate, and temperature) acquired first as the baseline at the preadmission session and then at predetermined intervals (10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours) after the injection of Sonazoid during scanning sessions 1 and 2 as well as finally once again at scanning session 3. The volunteers had a complete blood analysis, consisting of a complete blood count, blood coagulation profile (prothrombin time and partial thromboplastin time), and comprehensive metabolic panel collected at 4 different time points of the study: preadmission session, scan session1, scan session 2, and scan session 3. Also, a urinalysis was performed at the same time points as the blood analysis. All of these values were compared by 2 physicians with the normal ranges of values within the general population.
Data Analysis
Still images and digital clips from the US examinations were deidentified and randomized so that the readers would not be able to determine the case number. Three independent and blinded readers (2 physicians and 1 physicist: P.M., J.B.L., and F.F., with combined experience in contrast enhanced breast imaging of >50 years) analyzed the clips 4 to 6 months later and identified the number of SLNs observed during all the scanning days and time points. The number of SLNs and the time at which they were first identified were compared between the doses and between the readers by paired t tests, ANOVA, and j statistics. The AEs were analyzed in 2 different ways: firstly as the individual volunteer experiences during the entire study and secondly by the contrast agent dose received at that point of the study. Vital signs, blood analysis results, and urinalysis results were compared with the normal ranges in the general population. All tests were performed with Stata version 12.1 software (StataCorp, College Station, TX), with P < .05 indicating statistical significance.
Results
Participant Characteristics
All 12 volunteers were female. Their mean age was 47 years (range, 23-64 years). Figure 2 shows an example of SLNs and LCs detected with the low and high doses (in 2 different volunteers). A total of 48 SLNs were detected during the entire study; 22 were identified with the 1 mL dose and 26 with the 2 mL dose, for averages of 1.8 and 2.2 SLNs per dose, respectively (range, 1-4 SLNs detected per 
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injection). There were no significant differences in the numbers of SLNs detected when doses and readers were compared (P 5 .74 and .50, respectively; j 5 0.50-0.74). However, as different breasts of the same volunteer received different doses, this study did not compare how the same SLN could be identified by different doses, but, rather, the ability to visualize SLNs with different doses was compared. Figure 3 shows the same SLN imaged at the different time points associated with the 2 mL injection, from immediately after the Sonazoid injection ending at 24 hours after injection. Given the attempt to acquire the best image at any time point (considering the differences between the intensity of the contrast enhancement observed over time), there are some differences between the images related to focal zones and the gain used.
The time for the initial detection of SLNs based on dose is shown in Figure 4 . For the 1 mL dose, 100% of the SLNs were detected within the first hour, whereas for the 2 mL dose, 89% of the SLNs were detected in that period. There were no significant differences between doses or readers for the time of detection (P > .57), with j values showing agreement between readers for the time for the initial detection varying from 0.51 to 0.62.
Adverse Experiences
Only minor local and nonsignificant AEs confined to the injection site and surrounding area were encountered by the volunteers. All AEs were completely resolved without any intervention by the time the study was completed. Table 1 details the AEs that the volunteers encountered that were considered to be related to the contrast agent injection. The data are shown as total volunteers and also per dose to demonstrate that there were no significant differences between doses when AEs were compared (P > .50).
Three volunteers reported other AEs that were not considered related to the contrast agent injections (and therefore were not included in Table 1 ). These were cough (n 5 3), toothache (n 5 2), sore throat (n 5 1), and bronchitis (n 5 1). Vital Signs, Blood Analysis, and Urinalysis The analysis of the vital signs showed no significant alterations in the volunteers' blood pressure, heart rate, respiratory rate, and temperature when preinjection and postinjection values were compared (P > .50). The mean values of the vital signs are summarized in Table  2 . Likewise, the blood analysis and urinalysis showed no significant differences when preinjection and postinjection values were compared (P > .50), and the values remained in the normal ranges when compared with the general population during the entire study (Tables 3  and 4 ).
Discussion
The presence and extent of axillary LN involvement remain the most powerful predictors of recurrence and survival in breast cancer. 29, 30 Studies have shown that the presence of regional metastases within the axillary basin decreases a patient's 5-year survival by approximately 28% to 40%. 30 There are a few factors that can be use as predictors of node metastases, such as tumor size, lymphovascular invasion, tumor grade, and patient age. However, currently there is no combination of predictors of the axillary node status that can replace the histopathologic examination of the LNs. 29 An accurate assessment of the nodes is important not only for staging and prognosis but also for guiding treatment selection. 29 The accurate assessment of possible affected LNs that need to be removed is essential so that only the affected LNs are removed to minimize the anatomic disruption caused by axillary LN dissection, which can result in lymphedema, nerve injury, shoulder dysfunction, and other complications that may compromise functionality and the quality of life. 29 This issue is particularly troublesome when considering the fact that LN metastases are found in only 40% of patients who undergo axillary LN dissection. The remaining patients derive no therapeutic benefit from the procedure, whereas all patients are exposed to the complications described above. 30 Ultrasound examination is an economically viable, safe, and well-accepted technique for both patients and health care providers. Our studies have shown that CEUS represents a practical method for mapping the lymphatic drainage of tumors in real time, which could enable targeted preoperative US-guided biopsy of SLNs in patients with breast cancer. However, no dedicated safety studies have, to the best of our knowledge, been reported. Hence, this study aimed to evaluate the subdermal use of Sonazoid in CEUS to identify SLNs and, therefore, to be used in the future as an alternative to blue dye and/or radiopharmaceuticals. The safety of UCAs by intravascular or intravesical administration has been studied extensively, [31] [32] [33] [34] [35] [36] and the safety profile is excellent, with a low incidence of AEs. The side effects reported with UCAs are, in general, nonserious and transient and resolve spontaneously without residual effects. [31] [32] [33] [34] [35] [36] Recently, a few studies focused on the use of UCAs to evaluate the presence of SLNs in humans with breast cancer, where the UCA was injected subdermally around the areola (unlike this study), and the LCs were followed to the axilla for the identification of SLNs. [24] [25] [26] [27] [28] 37 These studies demonstrated accuracy of SLN detection varying from 70% to 100%. This variation may be due to the different locations on the breast for the injections, as well as the times of the injections. [24] [25] [26] [27] [28] 37 Safety assessments were not the main point of these studies; nonetheless, the investigators reached the same conclusion as our study in that only a few minor AEs were observed, and these completely resolved on their own without any intervention. [24] [25] [26] [27] [28] Our study showed similar findings when safety was evaluated, in which the few AEs observed were minor and completely resolved on their own without any intervention. That finding was independent of the Sonazoid dose used. Also, when we compared the number of SLNs that were identified by the 2 doses there was no significant difference. Therefore, using the concept of ALARA (as low as reasonably achievable), we selected the lower dose of 1 mL as the best dose in this study. We acknowledge that not all possible doses were evaluated, but between the 2 doses analyzed, there was no difference in their accuracy; therefore, the lower dose was chosen for future studies of patients with breast cancer.
In conclusion, the aim of this study was to evaluate the subdermal use of Sonazoid for SLN identification, with the focus on the safety of this method for lymphosonography, and the results showed that the volunteers only had minor local and nonsignificant AEs confined to the injection site and surrounding area that were completely resolved without any intervention by the time the study was completed. Two different doses were compared, and there was no significant difference in the number of SLNs detected (P 5 .74). Therefore, the lower dose of 1 mL was selected as the best dose (of the 2 studied here), and that will be the dose used in future clinical studies.
